ATE185151T1 - Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten - Google Patents

Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten

Info

Publication number
ATE185151T1
ATE185151T1 AT96920822T AT96920822T ATE185151T1 AT E185151 T1 ATE185151 T1 AT E185151T1 AT 96920822 T AT96920822 T AT 96920822T AT 96920822 T AT96920822 T AT 96920822T AT E185151 T1 ATE185151 T1 AT E185151T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
cartilage destruction
cell
treating
cells
Prior art date
Application number
AT96920822T
Other languages
English (en)
Inventor
Gijsbertus Francisc Verheijden
Anna Maria Helena Boots
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE185151T1 publication Critical patent/ATE185151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT96920822T 1995-06-19 1996-06-17 Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten ATE185151T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95201656 1995-06-19

Publications (1)

Publication Number Publication Date
ATE185151T1 true ATE185151T1 (de) 1999-10-15

Family

ID=8220392

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96920822T ATE185151T1 (de) 1995-06-19 1996-06-17 Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten

Country Status (21)

Country Link
EP (1) EP0833842B1 (de)
JP (1) JPH11507919A (de)
KR (1) KR19990022972A (de)
CN (1) CN1155617C (de)
AT (1) ATE185151T1 (de)
AU (1) AU704942B2 (de)
BR (1) BR9608626A (de)
CA (1) CA2221981A1 (de)
DE (1) DE69604492T2 (de)
DK (1) DK0833842T3 (de)
ES (1) ES2139363T3 (de)
GR (1) GR3031990T3 (de)
HU (1) HU223275B1 (de)
IL (1) IL118524A (de)
MX (1) MX9710508A (de)
NO (1) NO975968D0 (de)
NZ (1) NZ311022A (de)
PL (1) PL185258B1 (de)
TR (1) TR199701658T1 (de)
WO (1) WO1997000270A1 (de)
ZA (1) ZA965163B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CN1810832B (zh) 1998-10-23 2012-12-12 麒麟-安姆根有限公司 与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
IL132611A0 (en) * 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules

Also Published As

Publication number Publication date
KR19990022972A (ko) 1999-03-25
NO975968L (no) 1997-12-18
PL185258B1 (pl) 2003-04-30
IL118524A0 (en) 1996-09-12
CN1188483A (zh) 1998-07-22
MX9710508A (es) 1998-03-31
TR199701658T1 (xx) 1998-06-22
HU223275B1 (hu) 2004-04-28
DE69604492T2 (de) 2000-04-13
NO975968D0 (no) 1997-12-18
NZ311022A (en) 1999-11-29
HUP9802197A3 (en) 1999-06-28
PL324208A1 (en) 1998-05-11
AU704942B2 (en) 1999-05-06
DK0833842T3 (da) 2000-04-03
ES2139363T3 (es) 2000-02-01
WO1997000270A1 (en) 1997-01-03
EP0833842B1 (de) 1999-09-29
BR9608626A (pt) 1999-06-15
EP0833842A1 (de) 1998-04-08
CN1155617C (zh) 2004-06-30
DE69604492D1 (de) 1999-11-04
IL118524A (en) 2004-02-19
HUP9802197A2 (hu) 1999-02-01
ZA965163B (en) 1997-01-23
GR3031990T3 (en) 2000-03-31
JPH11507919A (ja) 1999-07-13
CA2221981A1 (en) 1997-01-03
AU6224696A (en) 1997-01-15

Similar Documents

Publication Publication Date Title
DE69326064T2 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
AU4644689A (en) Hybrid procoagulant proteins
DE69629181D1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
BR9506377A (pt) Peptídeo compreendendo uma subsequéncia de gp-39 hc proteina gp-39 hc ou peptideos composição farmacéutica uso da proteina gp-39 hc ou um ou mais dos peptídeos composição de diagnostico e processo de diagnóstico e kit de teste para a detecção de céçiças t auto-reativas ativadas
NZ332427A (en) Peptides suitable for use in antigen specific immunosuppressive therapy
DE69331813T4 (de) Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen
ATE185151T1 (de) Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ES2145061T3 (es) Diagnostico y terapia a base de peptidos para el tratamiento de las espondiloartropatias.
TR200100175T2 (tr) Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
DE69631624D1 (de) Antikörper gegen menschliches restrictin
DE69813620D1 (de) Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten
ECSP993062A (es) Nuevos peptidos para ser usados en una terapia de tolerancia inducida para impedir las alteraciones autoinmunes, en particular, artritis reumatoidea

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee